BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 9339684)

  • 21. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
    Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
    JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I.
    Tuomi T; Björses P; Falorni A; Partanen J; Perheentupa J; Lernmark A; Miettinen A
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1488-94. PubMed ID: 8636356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.
    Powers AC; Bavik K; Tremble J; Daw K; Scherbaum WA; Banga JP
    Clin Exp Immunol; 1999 Dec; 118(3):349-56. PubMed ID: 10594551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The insulin-dependent diabetes mellitus-associated ICA 105 autoantigen in stiff-man syndrome patients.
    Martino G; Grimaldi LM; Bazzigaluppi E; Passini N; Sinigaglia F; Rogge L
    J Neuroimmunol; 1996 Sep; 69(1-2):129-34. PubMed ID: 8823384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutamic acid decarboxylase antibody-associated neurological syndromes: Clinical and antibody characteristics and therapy response.
    Madlener M; Strippel C; Thaler FS; Doppler K; Wandinger KP; Lewerenz J; Ringelstein M; Roessling R; Menge T; Wickel J; Kellingshaus C; Mues S; Kraft A; Linsa A; Tauber SC; Berg FT; Gerner ST; Paliantonis A; Finke A; Priller J; Schirotzek I; Süße M; Sühs KW; Urbanek C; Senel M; Sommer C; Kuempfel T; Pruess H; Fink GR; Leypoldt F; Melzer N; Malter MP;
    J Neurol Sci; 2023 Feb; 445():120540. PubMed ID: 36608627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-GAD positive stiff-person syndrome and cerebellar ataxia: two treatable conditions that clinicians should be aware of.
    Ferraz HB
    Arq Neuropsiquiatr; 2012 Sep; 70(9):655-6. PubMed ID: 22990718
    [No Abstract]   [Full Text] [Related]  

  • 27. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.
    Tremble J; Morgenthaler NG; Vlug A; Powers AC; Christie MR; Scherbaum WA; Banga JP
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2664-70. PubMed ID: 9253351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibodies to glutamic acid decarboxylase (GAD) detected by an immuno-trapping enzyme activity assay: relation to insulin-dependent diabetes mellitus and islet cell antibodies.
    Martino GV; Tappaz ML; Braghi S; Dozio N; Canal N; Pozza G; Bottazzo GF; Grimaldi LM; Bosi E
    J Autoimmun; 1991 Dec; 4(6):915-23. PubMed ID: 1812896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [IA-2 and anti-GAD antibodies in patients with newly diagnosed type 1 diabetes and their first degree relatives].
    Kretowski A; Kowalska I; Peczyńska J; Urban M; Kinalska I
    Przegl Lek; 2000; 57(3):143-6. PubMed ID: 10909282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies to IA-2 in insulin-dependent diabetes mellitus. Measurements with a new immunoprecipitation assay.
    Masuda M; Powell M; Chen S; Beer C; Fichna P; Rees Smith B; Furmaniak J
    Clin Chim Acta; 2000 Jan; 291(1):53-66. PubMed ID: 10612717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
    Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
    J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.
    Peltola J; Kulmala P; Isojärvi J; Saiz A; Latvala K; Palmio J; Savola K; Knip M; Keränen T; Graus F
    Neurology; 2000 Jul; 55(1):46-50. PubMed ID: 10891904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome.
    Richter W; Seissler J; Northemann W; Wolfahrt S; Meinck HM; Scherbaum WA
    Diabetes; 1993 Nov; 42(11):1642-8. PubMed ID: 8405707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The neurological syndromes associated with glutamic acid decarboxylase antibodies.
    Baizabal-Carvallo JF
    J Autoimmun; 2019 Jul; 101():35-47. PubMed ID: 31000408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between antibodies to the MR 67,000 isoform of glutamate decarboxylase (GAD) and type 1 (insulin-dependent) diabetes mellitus with coexisting autoimmune polyendocrine syndrome type II.
    Seissler J; Bieg S; Yassin N; Mauch L; Northemann W; Boehm BO; Scherbaum WA
    Autoimmunity; 1994; 19(4):231-8. PubMed ID: 7578849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association.
    Piquer S; Belloni C; Lampasona V; Bazzigaluppi E; Vianello M; Giometto B; Bosi E; Bottazzo GF; Bonifacio E
    Clin Immunol; 2005 Oct; 117(1):31-5. PubMed ID: 16027042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies.
    Iwasaki H; Sato R; Shichiri M; Hirata Y
    Endocr J; 2001 Apr; 48(2):261-8. PubMed ID: 11456277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: A comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus.
    Nakajima H; Nakamura Y; Inaba Y; Tsutsumi C; Unoda K; Hosokawa T; Kimura F; Hanafusa T; Date M; Kitaoka H
    J Neuroimmunol; 2018 Apr; 317():84-89. PubMed ID: 29338930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain-reactive autoantibodies in BB/d rats do not recognize glutamic acid decarboxylase.
    Davenport C; Lovell H; James RF; Todd I
    Clin Exp Immunol; 1995 Jul; 101(1):127-35. PubMed ID: 7621582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical differentiation of monoclonal GAD antibodies recognizing linear or conformational epitope regions.
    Augstein P; Ziegler B; Schlosser M; Flassig S; Strebelow M; Ziegler M
    Pancreas; 1997 Aug; 15(2):139-46. PubMed ID: 9260198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.